Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients

Abstract

cfDNA tumor fraction can inform the interpretation of negative cfDNA results and guide the selection of subsequent sequencing platforms that are most likely to identify clinically-relevant genomic alterations.